Dublin, Aug. 22, 2017 -- The "Worldwide Adult Vaccines Market: Company Adult Vaccines Sales, Country Adult Vaccines, and Analysis" report has been added to Research and Markets' offering.
Adult Vaccines Market is expected to be close to US$ 20 Billion by the year 2022
Because of vaccines, some diseases (like Polio and Diphtheria) are becoming rare. Vaccination can prevent certain deadly diseases in all age groups. Almost all countries around the world have introduced efficient National Immunization Programme in their vaccination schedule to overcome the epidemics caused by vaccine-preventable diseases. WHO's Global Vaccine Action Plan, Global Immunization Vision and Strategy (GIVS), The GAVI Alliance all are putting their best to minimize the incidence of vaccine-preventable diseases which indeed is driving the adult vaccine market vigorously.
"Influenza Vaccine Leads the Adult Vaccine Market for the Year 2017"
Influenza vaccine is dominating the adult vaccine segment in year 2017, however it will lose its place to Pneumococcal vaccine in the coming future as admissions for pneumonia had almost tripled over the last 15 years. Other than Influenza and Pneumococcal Vaccines, Cervical Cancer (HPV), Hepatitis and Travel vaccines also have considerable market share in adult vaccines market.
"Considerable Growth in Immunization of Cervical Cancer (HPV), Zoster, Meningococcal, Hepatitis, Tdap and MMRV Vaccines"
In terms of Immunization; Influenza holds the maximum share as influenza vaccination is recommended to take annually in almost all countries of the world. However, with the growing awareness and efficiency of vaccines in preventing diseases, our analysis found that there will be considerably growth in the number for people opting for Cervical Cancer (HPV), Zoster, Meningococcal, Hepatitis, Tdap and MMRV vaccines in future till 2022.
"Administration of Vaccines Doses"
Influenza Vaccine holds the topmost place while talking about the administration of vaccine doses as influenza strains change every year and people needs to get an updated influenza shot each year to stay protected. Expect Influenza; Cervical Cancer (HPV), Pneumococcal and Hepatitis vaccines have remarkable administration doses.
'Worldwide Adult Vaccines Market: Company Adult Vaccines Sales, Country Adult Vaccines, and Analysis' is the 2nd publication on Adult Vaccines Market. This 181 pages research report with 77 Figures and 32 Tables provides a complete analysis of Adult Vaccines Market, Immunization Numbers in People, Number of Vaccine Doses Administered in Adults (Disease wise) & Key Players Analysis.
Key Questions Answered In This Report:
- What will be the Market Size of Global Adult Vaccine by the year 2022?
- What are the Key Drivers & Challenges for Adult Vaccines Market?
- Who are the key players in Adult Vaccine Market?
- What products are in key Players Pipeline?
Adult Vaccines in the Report have been studied from 3 Viewpoints:
1. Global Adult Vaccines (Disease wise) Market & Forecast (2011 - 2022)
2. People Immunized (Disease wise) & Forecast (2011 - 2022)
3. Doses of Vaccines Administered (Disease wise) & Forecast (2011 - 2022)
9 Vaccines Studied in the Report are as Follows:
1. Influenza
2. Cervical Cancer
3. Zoster (Shingles)
4. MMRV (Measles, Mumps, Rubella and Varicella)
5. Pneumonia
6. Meningitis
7. Hepatitis
8. DTap (Diphtheria, Tetanus, Pertussis)
9. Travel & Miscellaneous Vaccine
Companies Vaccines Sales and Forecast:
1. GlaxoSmithKline, plc Sales & Forecast (2011 - 2022)
2. Merck & Co. Sales & Forecast (2011 - 2022)
3. Sanofi Pasteur's Sales & Forecast (2011 - 2022)
4. Pfizer, Inc.'s Sales & Forecast (2011 - 2022)
5. Others Vaccines
For more information about this report visit https://www.researchandmarkets.com/research/jqmh8q/worldwide_adult
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Vaccines


Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Washington Post Publisher Will Lewis Steps Down After Layoffs
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 



